DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Exercise in OI

Information source: Vanderbilt University
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Orthostatic Intolerance; Postural Tachycardia Syndrome

Intervention: Propanolol (Drug); Placebo (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Vanderbilt University

Summary

The main limitation patients with orthostatic intolerance (OI, or postural tachycardia syndrome, POTS) have to exercise is related to their increase in heart rate when standing. Main pharmacological treatment today is aimed at reducing heart rate with the use of betablockers (propanolol), this theoretically could also improve their exercise capacity; if their heart rate do not increase as much with the medication, they could exercise more. In addition, it has been suggested that in healthy volunteers subjected to head down tilt for 2 weeks (situation that produces a "simulated" transient POTS-like state) a single bout of intense exercise can improve orthostatic tolerance the day after exercising. The mechanisms involved in such response are not that clear but could be an increase in plasma volume already diminished in POTS patients. It seems likely that the same could be true for POTS patients.

The purpose of the present study are to pharmacologically improve the amount of exercise POTS patients can perform by reducing their baseline heart rate (specific aim 1) and to evaluate next day heart responses to an acute bout of intense exercise.

Therefore, the specific aims of this study are:

1. To test the hypothesis that lowering heart rate response with propanolol will result in an increase in exercise capacity.

2. To test the hypothesis that a single bout of exercise will result in an improvement in orthostatic tolerance the day after exercising.

Clinical Details

Official title: Effects of Exercise in Orthostatic Intolerance

Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Efficacy Study

Primary outcome: Maximal Oxygen Consumption Capacity (VO2 max)

Secondary outcome: Heart rate in response to the intervention

Detailed description:

- Subjects will be studied twice, once after receiving placebo and in a second occasion

after receiving propanolol.

- An exercise capacity test with estimation of maximal oxygen consumption (VO2 max) will

be done within 1 hour of receiving a pill containing placebo and that will be in appearance identical to the one for propanolol. This test will be conducted on a stationary bicycle and the effort will be gradually increased while expired air is measured during exhaustive physical work. The test will last approximately 30 minutes and be conducted in Vanderbilt's Clinical Trial Center.

- The day before and the day after the exercise test subjects will be asked to collect

urine for 12 hours each time and to keep a record of how much liquid they ingest.

- Posture study tests (measurements of heart rate and blood pressure taken while lying

down and at intervals for up to 30 minutes while standing) will be done the day before and the day after the exercise test.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Meet diagnostic criteria of POTS (Raj, et al., 2005)

- Age between 18-65 years

- Male and female are eligible (although the majority of patients POTS are female).

- Able and willing to provide informed consent

Exclusion Criteria:

- Presence of medical conditions that can explain postural tachycardia (e. g.,

dehydration, medications)

- Pregnancy

- Other factors which in the investigator's opinion would prevent the subject from

completing the protocol.

- Patients who are bedridden or chair-ridden.

Locations and Contacts

Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States; Recruiting
Alfredo Gamboa, MD, Email: adcresearch@vanderbilt.edu
Alfredo Gamboa, MD, Sub-Investigator
Luis Okamoto, MD, Sub-Investigator
Andre Diedrich, M.D. Ph.D., Sub-Investigator
Ginnie Farley, Sub-Investigator
Italo Biaggioni, MD, Principal Investigator
Additional Information

Starting date: November 2008
Ending date: November 2012
Last updated: April 8, 2009

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012